工業技術研究院

技術簡介

蛋白質降解藥物(含候選藥物)及前臨床評估技術可應用於癌症及其他疾病治療，例如：去勢抗性前列腺癌。蛋白質降解藥物之藥物設計合成/藥效/藥動/毒理/劑型/試量產等評估技術，可應用於藥物篩選與新藥研發。

Abstract

The novel PRTOAC drugs, including the candidate drug AR-148, induce degradation of AR/AR-V7 for cancer therapy and other disease treatments. The pre-clinical evaluation platform, encompassing design and synthesis, pharmacodynamics, pharmacokinetics, toxicological evaluation, and pilot production technology, can be effectively utilized for drug screening and the development of new pharmaceuticals.

技術規格

蛋白質降解藥物或候選藥物 1. 於去勢抗性前列腺癌模式 CWR22RV1 (enzalutamide-resistant 及高表現 AR-V7) 及 VCaP (高表現 AR) 完成概念驗證 。2. 具抑制腫瘤生長能力。3. 具口服給藥能力，無明顯副作用。4. 試量產。5.其他疾病治療潛力。

Technical Specification

An orally bioavailable candidate AR/AR-V7 PROTAC drug has demonstrated efficacy in a castration-resistant prostate cancer model. This compound efficiently degraded both AR and AR-V7 proteins in vitro, inhibited AR-dependent cell proliferation, and significantly impeded tumor growth in an animal model. The compound is currently undergoing pilot production for further development in this field. Moreover, this technology or candidate exhibits potential for treating other diseases

技術特色

蛋白質降解藥物(含候選藥物)及前臨床評估技術可應用於癌症及其他疾病治療，例如：去勢抗性前列腺癌。蛋白質降解藥物之藥物設計合成/藥效/藥動/毒理/劑型/試量產等評估技術，可應用於藥物篩選與新藥研發。

應用範圍

新藥開發

接受技術者具備基礎建議（設備）

藥物開發相關軟硬體，合成反應槽、分析儀器設備

接受技術者具備基礎建議（專業）

新藥開發經驗，分析化學

聯絡資訊